We read with great interest the paper by Smieszek and colleagues aimed to study the distribution of IL-6 at baseline in hospitalized COVID-19 patients and the role of genetic variants associated with attenuated IL-6 response [1]. The Authors reported worse outcome in patients with elevation of IL-6 (>150 pg/ml) and in carriers of specific allelic variants of IL6/IL6R, thus hypothesizing that these might be a biomarker of earlier intervention with anti-IL-6 drugs.
Hemoperfusion during veno-venous ECMO in severe COVID-19 with IL-6 elevation / Giordano, G.; Alessandri, F.; Pugliese, F.. - In: CYTOKINE. - ISSN 1043-4666. - 152:(2022), p. 155813. [10.1016/j.cyto.2022.155813]
Hemoperfusion during veno-venous ECMO in severe COVID-19 with IL-6 elevation
Giordano G.
;Alessandri F.;Pugliese F.
2022
Abstract
We read with great interest the paper by Smieszek and colleagues aimed to study the distribution of IL-6 at baseline in hospitalized COVID-19 patients and the role of genetic variants associated with attenuated IL-6 response [1]. The Authors reported worse outcome in patients with elevation of IL-6 (>150 pg/ml) and in carriers of specific allelic variants of IL6/IL6R, thus hypothesizing that these might be a biomarker of earlier intervention with anti-IL-6 drugs.| File | Dimensione | Formato | |
|---|---|---|---|
|
Pugliese_Severe-COVID-19_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.23 MB
Formato
Adobe PDF
|
1.23 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
